Highest-materiality recent filing
FinTrade Sherpa borrows $74,811.50 from largest shareholder, pledges IP collateral
Borrowed $74,811.50 principal from Lode Star Gold (largest shareholder) at 15.0015% annual interest, maturing March 31, 2028.
FinTrade Sherpa issues 227M shares, completes Phase 1 software, moves to beta
Issued 227M shares on Jan 23, 2026 per prior Asset Purchase Agreement for AI intellectual property.
Lode-Star Mining acquires FinTradeSherpa AI platform for 227M shares; pivots from mining to fintech
Acquired all intellectual property and rights to FinTradeSherpa AI-powered financial predictions platform from Tarka L'Herpiniere for 227,000,000 shares of common stock.
Lode-Star Mining appoints Davidson & Company as new auditor after Smythe resigns
Former auditor Smythe LLP resigned on Dec 6, 2024 due to a change in its policies.
Lode-Star Mining auditor Smythe LLP resigns due to policy change; no disagreements
On Dec 10, 2024, Smythe LLP resigned as auditor due to a change in its policy for SEC registrant audits.
CFO and Corporate Secretary Samuel Sternheim resigns; Mark Walmesley reappointed
Samuel Sternheim resigned as CFO, Corporate Secretary, and board member effective October 6, 2022.
Rescinded Sapir Pharmaceuticals asset purchase and royalty agreements on June 6, 2022; neither party has further obligations.
CEO Dr. Liora Zilberson resigns; Mark Walmesley reappointed CEO of Lode-Star Mining
Dr. Liora Zilberson resigned as Director and CEO effective April 1, 2022.
Dr. Liora Zilberson appointed CEO and director; receives 10,000,000 shares and monthly salary of 35,000 New Israel Shekels.
Lode-Star appoints Samuel Sternheim as director, CFO, and Corporate Secretary
Samuel Sternheim appointed to the Board of Directors effective January 14, 2022.
Lode-Star terminates Goldfield Bonanza Option, returns 20% interest, gets $2.224M debt forgiveness
Terminated Option Agreement with Lode Star Gold; returns its 20% undivided interest in Goldfield Bonanza Project in Nevada.
Acquired all assets related to stabilized EGCG molecule for pharmaceutical development.
Mr. Mark Walmesley was reappointed as the Chief Financial Officer and Corporate Secretary of the Company.
On October 6 th Mr. Samuel Sternheim submitted his resignation as the Chief Financial Officer, Corporate Secretary, and a member of the Board of the Company.
Upon the resignation of Dr. Liora Zilberson as the principal executive officer and a member of the Board of the Company, Mark Walmesley was reappointed as the Chief Executive Officer and President of the Company.
Upon the resignation of Dr. Liora Zilberson as the principal executive officer and a member of the Board of the Company, Mark Walmesley was reappointed as the Chief Executive Officer and President of the Company.
Effective as of February 18, 2022, the Board appointed Liora Zilberson as the Chief Executive Officer of the Company and as member to the Board of Directors of the Company.
On February 17, 2022, Thomas Temkin notified the Company that he was resigning as the Chief Operating Officer and from the Board of Directors of the Company, effective February 18th, 2022.
Upon appointment of Dr Zilberson, Mark Walmesley immediately steps down as CEO and continues service the Company as President.
Samuel Sternheim was appointed as a director of the Company effective as of January 14, 2022. On said date, Mr. Sternheim was also appointed as the chief financial officer of the Company.
it has appointed Mr. Samuel Sternheim as a member of the Board of Directors effective January 14, 2022.
Mr. Sternheim will also be assuming the roles of Corporate Secretary, Chief Financial Officer and Treasurer.
Max materiality 1.00 · Median 0.62 · Most common event other_material